{"id":34617,"date":"2025-06-03T17:44:47","date_gmt":"2025-06-03T09:44:47","guid":{"rendered":"https:\/\/flcube.com\/?p=34617"},"modified":"2025-06-03T17:44:48","modified_gmt":"2025-06-03T09:44:48","slug":"alphamab-oncology-presents-jskn003-clinical-data-at-2025-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34617","title":{"rendered":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting"},"content":{"rendered":"\n<p>Alphamab Oncology (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>The JSKN003-101 and JSKN003-102 studies, conducted in Australia and China, respectively, demonstrated that JSKN003 exhibited high objective response rates (ORR) and disease control rates (DCR) across different indications and HER2 expression levels. The drug showed a favorable safety profile, with most adverse events being mild to moderate. The incidence of severe adverse events was low, and no treatment-related deaths were reported.<\/p>\n\n\n\n<p><strong>JSKN003 Mechanism and Development<\/strong><br>JSKN003 is a HER2 bispecific epitope antibody-drug conjugate (ADC) designed to enhance binding affinity by targeting two distinct epitopes on HER2. This mechanism improves drug internalization and bystander killing effects, strengthening antitumor activity against HER2-expressing solid tumors while maintaining good serum stability. JSKN003 is currently the subject of multiple Phase III clinical trials in China, covering indications such as HER2-positive breast cancer, HER2-low breast cancer, and platinum-resistant recurrent epithelial ovarian cancer.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025060300018_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025060300018_c.\"><\/object><a id=\"wp-block-file--media-6b73f94c-3351-42cd-a17d-0de9da52fb80\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025060300018_c.pdf\">2025060300018_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025060300018_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6b73f94c-3351-42cd-a17d-0de9da52fb80\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,35,187,16,17,854],"class_list":["post-34617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-adc-xdc","tag-alphamab-oncology","tag-cancer","tag-clinical-trial-results","tag-hkg-9966"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34617\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34617\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T09:44:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T09:44:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting\",\"datePublished\":\"2025-06-03T09:44:47+00:00\",\"dateModified\":\"2025-06-03T09:44:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0313.webp\",\"keywords\":[\"Academic conference\",\"ADC \\\/ XDC\",\"Alphamab Oncology\",\"Cancer\",\"Clinical trial results\",\"HKG: 9966\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34617#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34617\",\"name\":\"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0313.webp\",\"datePublished\":\"2025-06-03T09:44:47+00:00\",\"dateModified\":\"2025-06-03T09:44:48+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34617\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0313.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0313.webp\",\"width\":1080,\"height\":608,\"caption\":\"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34617#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34617","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting","og_description":"Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.","og_url":"https:\/\/flcube.com\/?p=34617","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-03T09:44:47+00:00","article_modified_time":"2025-06-03T09:44:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34617#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34617"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting","datePublished":"2025-06-03T09:44:47+00:00","dateModified":"2025-06-03T09:44:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34617"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34617#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp","keywords":["Academic conference","ADC \/ XDC","Alphamab Oncology","Cancer","Clinical trial results","HKG: 9966"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34617#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34617","url":"https:\/\/flcube.com\/?p=34617","name":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34617#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34617#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp","datePublished":"2025-06-03T09:44:47+00:00","dateModified":"2025-06-03T09:44:48+00:00","description":"Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight the potential of JSKN003 across multiple indications, including platinum-resistant recurrent epithelial ovarian cancer (PROC), HER2-positive breast cancer previously treated with multiple lines of therapy, and gastrointestinal tumors with high HER2 expression.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34617#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34617"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34617#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp","width":1080,"height":608,"caption":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34617#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0313.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34617"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34617\/revisions"}],"predecessor-version":[{"id":34620,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34617\/revisions\/34620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34619"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}